Search

Search results

322 results found

The PTPN2/PTPN1 inhibitor ABBV-CLS-484 unleashes potent anti-tumour immunity

Publication: Journal Article

Baumgartner, Christina K., Hakimeh Ebrahimi-Nik, Arvin Iracheta-Vellve, Keith M. Hamel, Kira E. Olander, Thomas G. R. Davis, Kathleen A. McGuire, et al. 2023. “The PTPN2/PTPN1 Inhibitor ABBV-CLS-484 Unleashes Potent Anti-Tumour Immunity”. Nature 622 (7984): 850-62.

Discovering the anti-cancer potential of non-oncology drugs by systematic viability profiling

Page

https://depmap.org/repurposing/

Rishi Puram

Person: Postdoctoral Fellow

I am a postdoctoral fellow in the Golub lab using functional genomics and chemical screening approaches to define mechanism of action of epigenetic therapy in hematologic malignancies.

Research

Page

Nolan Priedigkeit

Person: Postdoctoral Fellow

I am a medical oncology fellow interested in understanding single-cell transcriptional heterogeneity to improve how we classify, diagnose and treat advanced breast cancers.

Choushi Wang

Person: Postdoctoral Fellow

I am a postdoctoral associate with a research focus on the tumor microenvironment, investigating strategies to manipulate it for therapeutic benefit.

Jung Won Park

Person: Research Associate I

Positions Available

Page

Current Openings: Thank you for your interest. Please keep an eye on this page for openings. We welcome inquiries from students and experienced scientists at all levels. Please send your inquiries to TRGapplications@broadinstitute.org, and please be sure to include what position you are interested...

Jenny Serra-Vinardell

Person: Research Scientist II

BRD-810 is a highly selective MCL1 inhibitor with optimized in vivo clearance and robust efficacy in solid and hematological tumor models.

Publication: Journal Article

Rauh, Ulrike, Guo Wei, Michael Serrano-Wu, Georgios Kosmidis, Stefan Kaulfuss, Franziska Siegel, Kai Thede, et al. 2024. “BRD-810 Is a Highly Selective MCL1 Inhibitor With Optimized in Vivo Clearance and Robust Efficacy in Solid and Hematological Tumor Models.”. Nat Cancer 5: 1479-93.